19
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      A mouse anti-myostatin antibody increases muscle mass and improves muscle strength and contractility in the mdx mouse model of Duchenne muscular dystrophy and its humanized equivalent, domagrozumab (PF-06252616), increases muscle volume in cynomolgus monkeys

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          The treatments currently approved for Duchenne muscular dystrophy (DMD), a progressive skeletal muscle wasting disease, address the needs of only a small proportion of patients resulting in an urgent need for therapies that benefit all patients regardless of the underlying mutation. Myostatin is a member of the transforming growth factor-β (TGF-β) family of ligands and is a negative regulator of skeletal muscle mass. Loss of myostatin has been shown to increase muscle mass and improve muscle function in both normal and dystrophic mice. Therefore, myostatin blockade via a specific antibody could ameliorate the muscle weakness in DMD patients by increasing skeletal muscle mass and function, thereby reducing patients’ functional decline.

          Methods

          A murine anti-myostatin antibody, mRK35, and its humanized analog, domagrozumab, were developed and their ability to inhibit several TGB-β ligands was measured using a cell-based Smad-activity reporter system. Normal and mdx mice were treated with mRK35 to examine the antibody’s effect on body weight, lean mass, muscle weights, grip strength, ex vivo force production, and fiber size. The humanized analog (domagrozumab) was tested in non-human primates (NHPs) for changes in skeletal muscle mass and volume as well as target engagement via modulation of circulating myostatin.

          Results

          Both the murine and human antibodies are specific and potent inhibitors of myostatin and GDF11. mRK35 is able to increase body weight, lean mass, and muscle weights in normal mice. In mdx mice, mRK35 significantly increased body weight, muscle weights, grip strength, and ex vivo force production in the extensor digitorum longus (EDL) muscle. Further, tibialis anterior (TA) fiber size was significantly increased. NHPs treated with domagrozumab demonstrated a dose-dependent increase in lean mass and muscle volume and exhibited increased circulating levels of myostatin demonstrating target engagement.

          Conclusions

          We demonstrated that the potent anti-myostatin antibody mRK35 and its clinical analog, domagrozumab, were able to induce muscle anabolic activity in both rodents, including the mdx mouse model of DMD, and non-human primates. A Phase 2, potentially registrational, clinical study with domagrozumab in DMD patients is currently underway.

          Related collections

          Most cited references12

          • Record: found
          • Abstract: found
          • Article: not found

          A Mutation in the Myostatin Gene Increases Muscle Mass and Enhances Racing Performance in Heterozygote Dogs

          Introduction The wide variety of behaviors and morphological types exhibited among dog breeds and the overall low genetic diversity within each breed make the dog an excellent genetic system for mapping traits of interest [1,2]. Recently, owners of whippets, an established racing-dog breed, have reported a phenotype of heavy muscling occurring within the breed (http://www.k9community.co.uk/forums/index.php). The typical whippet is similar in conformation to the greyhound, a medium-sized sighthound, weighing about 9 kg and characterized by a slim build, long neck, small head, and pointed snout (Figure 1A) [3]. Heavily muscled dogs, termed “bully” whippets by breeders, have broad chests and unusually well-developed leg and neck musculature (Figure 1C). “Bully” whippets are easily distinguished from their normal littermates based on physical appearance alone (compare Figure 1A and 1C). Owners report that “bully” whippets do not have any health abnormalities other than muscle cramping in the shoulder and thigh. However, the dogs are often euthanized at an early age as they do not conform to the American Kennel Club breed standard. In addition, about 50% of “bully” whippets have a distinctive overbite. The “bully” whippet phenotype is reminiscent of the double muscling phenotype seen in other species that is caused by mutations in the myostatin (MSTN) gene. Such variants have been observed in mice [4], cattle [5,6], sheep [7], and human, the latter described once in a German boy [8]. The myostatin protein has been shown to affect both the amount and composition of muscle fibers. For instance, the muscle mass of Mstn knockout mice is two to three times greater than that of wild-type mice [9]. Furthermore, the sequence of the MSTN gene is relatively conserved across species [9]. Therefore, we chose to interrogate the MSTN gene for possible mutations resulting in the “bully” whippet phenotype. Results MSTN Genotypes in the Whippet We sequenced the three exons and the majority of introns of the MSTN gene in an initial set of 22 whippets. A 2-bp deletion was discovered in the third exon of the MSTN gene (Figure 2). This deletion removes nucleotides 939 and 940 within exon three and leads to a premature stop codon at amino acid 313 instead of the normal cysteine, removing 63 aa from the predicted 375-aa protein. The lost cysteine is one of several highly conserved cysteines known to form disulfide dimers required for protein function [9]. Of the 22 whippets sequenced, all “bully” whippets tested (n = 4) were homozygous for the deletion (mh/mh) while all dogs that sired or whelped a “bully” whippet (n = 5) were heterozygous for the deletion (mh/+). None of the initial set of 13 normal-appearing whippets that lacked a family history of the “bully” phenotype carried the deletion; these dogs were designated wild type (+/+). An additional set of DNA samples from 146 whippets (both racers and nonracers) were collected at racing events and through the mail without regard to the dogs' family histories of the “bully” phenotype. These were sequenced across exon three to determine the frequency of the 2-bp mutation among the dogs sampled. Of these, two were homozygous for the deletion, 20 were heterozygous, and the remaining 124 did not carry the deletion. Mode of Inheritance and Heterozygote Phenotypes The “bully” phenotype displays a simple autosomal recessive mode of inheritance, as all “bullies” resulted from the mating of carriers. The parents have a phenotype of intermediate musculature (Figure 1B). In order to quantify the allelic substitution and dominance effects of the deletion mutation we considered three measures of musculature: mass-to-height ratio, neck girth, and chest girth. For all three measures, heterozygous females (mh/+) were intermediate in musculature, mh/mh females had the highest measures, and female +/+ whippets had the lowest measures. Male mh/+ whippets were more muscular than wild-type males (Figure 3 and Table 1). Mass (kg) and height at the withers (cm) information was available for 71 female and 55 male whippets; we analyzed the two sexes separately due to a lack of samples from male mh/mh whippets. Two analyses suggest strong statistical support for the idea that the mh deletion mutation affects the mass-to-height ratio. First, a nonparametric Kruskal-Wallis one factor Analysis of Variance for females using genotype as a factor (mh/mh, mh/+, and +/+) was highly significant (p ≈ 7.43 × 10−6) [10]. Likewise, a two-sample Wilcoxon rank sum test comparing mass-to-height ratio of mh/+ and +/+ males was also significant (p ≈ 0.00017), with whippets heterozygous for the mutation exhibiting, on average, 17% more mass per cm of height (i.e., 0.333 kg/cm for mh/+ as compared to 0.284 kg/cm for +/+ genotypes). Second, we used standard least-squares regression to estimate the allelic substitution (a = 0.0817; p < 2.44 × 10−15) and dominance effects (d = −0.0423; p = 0.00415) in female whippets and found both parameters were significantly different than zero. These results, along with box plots of the phenotype by genotype class (Figure 3), suggest that the mutation is partially recessive with heterozygotes (mh/+) having musculature closer to, but significantly different from, that of wild types (+/+). As reported in Table 1, we found that the mh mutation also affected neck and chest girth in a similar fashion in females with a highly significant effect of MSTN genotype on phenotype. Overall, we estimate that mh explains approximately 60% of the variation in both mass-to-height ratio and neck girth (i.e., r 2 = 60%) and 31% of the variation in chest girth (Table 1). In male whippets, we also observed a highly significant difference in neck girth (p ≈ 0.0013, Wilcoxon rank sum test) and nearly significant difference in chest girth (p ≈ 0.11, Wilcoxon rank sum test) among wild type (+/+) and heterozygotes (mh/+). Association of Heterozygosity with Racing Speed We hypothesized that the increased muscle mass of the heterozygotes would allow for increased speed when compared to wild type (+/+) whippets. Analysis of 85 genotyped dogs for which we obtained racing grades revealed an association between a dog's genotype and racing grade using two separate (but not independent) approaches (Figure 4). Only one mh/mh dog competed in racing events and it was a grade-A racer, so we included this dog with the heterozygotes and considered the absence or presence of the deletion for all analyses (i.e., we sum across the mh/+ and mh/mh columns in Table 2. First, we find a significant positive correlation between racing grade (A, B, C, and D in order from fastest to slowest) and the frequency of dogs carrying the mh deletion in either homozygous or heterozygous state (p ≈ 0.00028, τ = 0.3619, Kendall's nonparametric measure). Secondly, standard contingency table analysis reveals strong evidence for heterogeneity in the frequency of dogs carrying the mh deletion among racing grade classes (Table 2; p = 0.00029, Fisher's exact test with degrees of freedom = 3). Since the 4 × 2 contingency table (i.e., combining columns two and three of Table 2) has three degrees of freedom, it is possible to partition the analysis into three tests of one degree of freedom each in order to identify outlier grades. There are several methods by which this can be accomplished, although they are not independent of each other. For example, 12 of 41 dogs in the fastest two racing grades, A and B, carried the deletion, while just one dog of 43 from the slowest two racing grades, C and D, was a heterozygote (p = 0.00073, Fisher's exact test), indicating a strong difference in frequency between (A, B) and (C, D). There is suggestive evidence for a difference between race grades A and B (p = 0.086, Fisher's exact test) but no evidence for a difference between C and D (p = 0.42, Fisher's exact test). A different approach for dividing the degrees of freedom is to compare A versus (B, C, D) (p = 0.00027, Fisher's exact test), C versus (B, D) (p = 0.099, Fisher's exact test), and C versus D (p = 0.42, Fisher's exact test). Thus, each of these two methods for partitioning the test suggests that the presence of the mh mutation strongly influences racing ability. There was also a marginally significant difference in the mutation genotype frequency in whippets that participated in racing versus conformation events such as breed club regional specialties, where dogs are judged based on their conformation to the physical breed standard (height at the withers or shoulder, head shape, coat color, etc.). Twenty of 119 confirmed racing whippets were heterozygous for the deletion while just two of 42 whippets that competed in conformation events were heterozygous (p = 0.038, one-tailed Fisher's exact test). Population Structure in the Whippet To investigate how population substructure within whippets affects our candidate gene analysis, we genotyped 32 unlinked microsatellite markers [11] in 84 whippets with racing grades. Analysis of FST revealed that whippets exhibit a low, but measurable, degree of population differentiation with higher levels of interbreeding within racing grades. As a result, genetic distance correlates with racing grade so that there is a moderate differentiation between A and B grades (FST = 0.021), little differentiation between B and C (FST = 0.0044) or C and D (FST = 0.0067) racers, and the largest difference between the population of A and D racing dogs (FST = 0.041). These levels of population differentiation are quite typical for mammalian species and are not surprising, given that whippets are bred to race and positive assortative mating is expected (i.e., fast dogs are bred to fast dogs). Analysis of the data using Structure [12] and InStruct [13] gave comparable results under a range of cluster numbers from K = 1 to K = 15. Neither program found a clustering that clearly correlated with racing grade. The neighbor-joining tree of the 84 dogs used in this analysis based on genetic similarity (i.e., kinship coefficient) tends to differentiate dogs within the A racing grade from those in other grades, but not in a fully exclusive manner (Figure S1). It also demonstrates that dogs carrying the 2-bp deletion are found on all branches of the tree and are not one another's closest relatives, although they do tend to cluster near one another on the tree. Logistic regression analysis of 73 alleles at moderate frequencies in the sample confirmed that population substructure may be a potentially confounding effect for association mapping within breeds of dog. In particular, we found that 26 of the alleles (36%) across the 32 loci show a nominal p-value of 5% or lower, a huge inflation above the expected 5% (Figure S2A). As a result, many of the 32 loci showed association with racing grade using standard contingency table analysis. However, the association of the 2-bp deletion with racing grade is more significant than all but one of these, suggesting an empirical p-value of 1/72 = 0.014 (Figure S2B). MSTN Genotypes in Other Breeds and Haplotype Construction We sequenced exon three of MSTN in a set of approximately four dogs each from heavily muscled breeds including the bullmastiff, rottweiler, bulldog, Presa Canario, miniature bull terrier, American Staffordshire terrier, and Staffordshire bull terrier. In addition, we sequenced exon three of MSTN in a small set of dogs from breeds known to compete in racing: the greyhound, lurcher, and two mixed-breed dogs (whippet crosses). None of these dogs possessed the 2-bp deletion seen in the whippet. To obtain haplotype information, we sequenced the MSTN gene and surrouonding area (Figure 5) in one to ten dogs each from the greyhound, Ibizan hound, Pharaoh hound, Afghan hound, saluki, Italian greyhound, mastiff, boxer, Akita, Basenji, Australian shepherd, beagle, German wirehaired pointer, and flat-coated retriever breeds. A golden jackal was also sequenced to determine the ancestral allele for each dog SNP and insertion/deletion (indel). None of the dogs sequenced from any of the above breeds nor the golden jackal possessed the 2-bp deletion. We discovered 28 SNPs and three indels. For the three indels and eight SNPs that were discovered within 50 kb of the MSTN mutation, we inferred haplotypes independently for each breed using PHASE. A total of 13 haplotypes were identified, but only six were observed in more than one breed. Two of these haplotypes are shared across several breeds. The MSTN mutation occurs on just one haplotype that is observed only in the whippet (Figure 5). A haplotype observed in 12 breeds differs from this one only at the mutation itself. Discussion The whippet breed was developed in the late 1800s specifically for the sport of racing [3]. Despite its comparatively small stature it is a very fast dog capable of running up to 35 miles per hour [3]. We have discovered a 2-bp deletion in the whippet MSTN gene that in the homozygote state results in a double-muscling phenotype commonly referred to as the “bully” whippet. This deletion causes a premature truncation of the protein at amino acid 313, removing the latter 17% of the protein. MSTN has been mapped to canine Chromosome 37 (CFA37) and consists of three exons spanning 5083 bp (http://genome.ucsc.edu). It is highly conserved across species [9] and in the human genome is located on Chromosome two. The gene is a member of the transforming growth factor β family and encodes the myostatin protein. Studies of Mstn knockout mice demonstrate that the gene is a negative regulator of skeletal muscle mass [9]. This is the result of a cascading pathway triggered by MSTN signaling that prevents myoblast cell progression from the G1 to S phase of the cell cycle. MSTN therefore controls the total number of muscle fibers by regulating overall myoblast proliferation [14]. In the absence of functional protein, greater numbers of muscle fibers are made [14]. Double muscling has been described in several breeds of cattle [5,6,15–17] and muscular hypertrophy (an increase in muscle-fiber size) has been described in sheep [7]. Muscular hypertrophy has also been described in the domestic cat [18]; however, a deficiency in dystrophin is the cause in this species rather than a mutation in MSTN. To date, six different mutations in the bovine MSTN gene have been reported to cause double muscling [5,6,15–17]. While all these mutations result in a loss of MSTN function, a subset of them and the one we describe here in the whippet likely change the three-dimensional shape of the protein by disrupting the “cysteine knot,” a structure important in the folding of all transforming growth factor β family member proteins [5,9]. The mutation in the whippet also removes nearly 20% of the protein. We sequenced genomic DNA not only from whippets but also from multiple dogs from each of 14 additional breeds in order to determine the haplotype background on which this mutation arose (Figure 5). In each dog, 15 PCR amplicons that spanned the MSTN gene and amplicons spanning known dog SNPs within 50 kb of the MSTN mutation were sequenced. Using the resulting data we observed two haplotypes, termed two and seven, that occurred in a large number of breeds and that were identical except at position 3,676,629, which is located outside the gene, 15,801 bp downstream from the 2-bp deletion. The mh mutation occurs only on haplotype six, which is identical to haplotype seven except for the deletion itself. Not surprisingly, the golden jackal sequence has only the wild-type allele at the position of the mutation, indicating the mh allele represents the derived state. We conclude therefore that haplotype six likely derives from haplotype seven (Figure 5). Haplotype seven is the most common and widely dispersed haplotype spanning the gene and was found in 12 out of 15 breeds sequenced. Interestingly, we did not observe haplotype seven in the Afghan hound, Basenji, or boxer. Our data do not exclude the possibility that the mutation occurs in breeds other than the whippet. However, we screened for the 2-bp deletion in several mastiff type breeds (rottweiler, bulldog, Presa Canario, miniature bull terrier, American Staffordshire terrier, Staffordshire bull terrier, and bullmastiff) and did not find it. These data argue that the changes in musculature exhibited by the whippet are unique and caused by the effects on MSTN associated with the deletion described in this study. An excess of the mh/+ genotype was observed among the fastest racers, as defined by the highest racing grade achieved during a dog's career. This demonstrates that the heterozygote state carries a performance-enhancing polymorphism that provides a competitive edge. The optimal study of racing performance would use the racing points acquired by each whippet during their career as a quantitative measure of performance. However a dog's total career points are a function of the number of races run throughout their career and, as such, whippets of different ages are not easily compared. To compensate, the total number of points accrued over a lifetime of racing could be averaged over the number of races entered. However, as dogs age their performance declines. Some owners stop racing their dogs after their performance declines while others continue to race their dogs for months or even years longer. Using the average number of points accrued during a specific year of the dog's life, for instance age two or three, presents similar problems. Dogs reach their racing prime at different ages and the number of points will always reflect the number of races entered. While an average is satisfactory if many races are run in a given year, the average will be inaccurate if few races are run. While cattle breeders have long selected for individuals that are homozygous for mutations in MSTN because of their increased musculature, which is optimal for beef production, this is the first example of breeders unknowingly selecting for individuals with a single polymorphism that increases athletic performance. Of interest, the trait appears to confer an undesirable appearance upon dogs competing in conformation. Only two mh/+ dogs were found among the dogs reported to compete in conformation events, and those dogs were reported to show poorly. This is consistent with the association seen between a dog's genotype and their relative muscle mass as defined by either a ratio of mass (kg) to height at the withers (cm) (p = 7.43 × 10−6; Kruskal-Wallis test) (Figure 3A) or the direct measure of an individual's neck girth (p = 3.47 × 10−5; Kruskal-Wallis test) (Figure 3B) or chest girth (p = 0.001462; Kruskal-Wallis test) (Figure 3C). We acknowledge that there are more accurate methods to measure muscle mass. However, many of these methods are either invasive, such as a muscle biopsy, or would need to be conducted post-mortem, neither of which was an option. These measurements were not designed to specifically eliminate contributions from body fat. However, obesity is rare in the whippet; indeed, the breed is characterized by an overall low body fat content. Thus, these measurements are the best achievable metrics of the phenotype. Greyhounds and whippets share a common ancestral gene pool and as a result the breeds are difficult to separate in genetic clustering analyses [11]. This, together with the fact that both were bred to excel at racing, suggested that the mutation might also be found in racing greyhounds. However, none of the greyhounds tested carried the mutation. There are three possible explanations for this result. First, an insufficient number of samples have been tested if the mutant allele is relatively rare in the greyhound population. Second, the mutation may only be present in a subset of greyhound lines, none of which were among those tested. Finally, the mutation may not be carried in the greyhound population at all, indicating that it is a relatively new mutation in the purebred dog population. This may be because the mutation offers no advantage to greyhound racers. Indeed, it may even be disadvantageous. Studies of muscle composition in Mstn knockout mice demonstrate a higher proportion of both fast type II and glycolytic fibers, versus slow type I and oxidative fibers when compared to wild-type mice [19]. While this change in muscle composition may offer an advantage to whippets, which typically race a short sprint of 200–300 m, it may be disadvantageous to greyhounds, whose races extend to 900 m and where endurance is more important. In addition, Belgian Blue cattle that are homozygous for a MSTN mutation display a decrease in the size of several organs, including the lungs [20]. If heterozygous dogs have even a slightly reduced lung capacity, it is possible that a MSTN mutation would actually be disadvantageous for racing longer distances as greyhounds do. Finally, it remains to be determined whether additional health problems are associated with being a carrier of this mutation. We examined the microsatellite data set for evidence of population substructure and found that there is not random gene flow across the racing classes. All groups display positive FST values with the greatest found between the grade A racers and all others. This is not unexpected. The very presence of the “bully” phenotype is evidence that breeders choose to mate dogs with increased musculature to one another. Reducing the mating population of a breed to a small proportion of the whole population has consequences, particularly for genetic mapping of complex traits. This is evidenced by our analysis of the same marker set for association with racing grade. While we find low p-values at many of the alleles, only one of 73 had a p-value smaller than the 2-bp deletion, confirming that the association between racing grade and the MSTN mutation is not simply a spurious result of population structure. Overall, these results suggest that the population structure within breeds is likely to have an important confounding effect on association mapping in the domestic dog. Our findings have implications for competitive and professional sports. Here, we show that a disruption in the function of the MSTN gene increases an individual's overall athletic performance in a robust and measurable way. To date, the muscular hypertrophy phenotype has been described in a single human child [8]. This child possessed two copies of a G-to-A transition in the noncoding region of the human MSTN gene. This mutation results in the mis-splicing of precursor mRNA, which most likely truncates the myostatin protein. The child's mother, a former professional athlete, was heterozygous for this mutation and also appeared muscular, although not to the same degree as her child. Perhaps additional mutations in MSTN have yet to be discovered in other species that competitively race, such as the horse or humans. As discussed by others [21,22], human athletes could undergo so-called gene doping via disruption of MSTN. The potential to increase an athlete's performance by disrupting MSTN either by natural or perhaps artificial means could change the face of competitive human and canine athletics. Given the poorly understood consequences for overall health and well-being, caution should be exercised when acting upon these results. Materials and Methods Sample collection. An initial set of 22 whole-blood samples were collected from whippets that participated in racing, conformation, or were simply privately owned pets. Of these 22 dogs, four were reported by owners to be “bullies,” five dogs had either sired or whelped a “bully,” and the owners of the remaining 13 stated there was no known family history of “bullies” in their dog's pedigree. After initial analysis of these 22 samples an additional 46 whole-blood samples and 100 buccal swabs were collected from a mixture of racing, conformation, and pet whippets. No restrictions were placed on age, gender, or relatedness of the dogs sampled. The dog's sex was recorded for 165 (98%) of the dogs (74 males and 91 females). Samples were collected both by mail and at sanctioned Whippet Racing Association (WRA), National Oval Track Racing Association (NOTRA), and Continental Whippet Alliance (CWA) racing events. Blood samples from each dog were collected as whole blood in ACD tubes. Buccal swabs were collected using standard protocols with Cytosoft cytology brushes (Medical Packaging Corporation, http://www.medicalpackaging.com). DNA was extracted from the brushes using a QIAamp Blood Mini kit (Qiagen, http://www.qiagen.com) following the manufacturer's protocol. DNA was extracted from the blood samples using a standard phenol/chloroform extraction method [23]. DNA samples were also collected from 33 greyhounds, two mixed-breed dogs (whippet crosses), seven lurchers, five each of bullmastiffs, rottweilers, and bulldogs, four each of Presa Canarios, miniature bull terriers, mastiffs, Staffordshire bull terriers, Ibizan hounds, and salukis, three each of American Staffordshire terriers, Italian greyhounds, boxers, and Pharaoh hounds, two each of Akitas, Afghan hounds, Australian shepherds, beagles, flat-coated retrievers, and German wirehaired pointers, a single Basenji, and a single golden jackal. Samples were either received as DNA from collaborators or DNA was extracted by the aforementioned methods after collection at dog shows, events, or provided directly by owners and breeders. Informed consent was obtained for all newly collected samples and all protocols were approved by the Animal Care and Use Committee of the Intramural Program of the National Human Genome Research Institute at the National Institutes of Health. Phenotype assessment. Owners of whippets were asked to provide detailed information about their dogs including American Kennel Club or other registration number, pedigree information, and the events in which their dogs participated. Front and side photos of individual dogs were obtained for comparison. The dog's mass and height at the withers were recorded for 126 dogs (55 males and 71 females). A set of body measurements including neck girth and chest girth were also collected from 137 of the whippets (61 male and 76 female) either by owners or laboratory members as described (N. B. Sutter, D. S. Mosher, and E. A. Ostrander; personal communication). There are four organizations that govern whippet racing in the United States; straight racing is sponsored by the WRA, CWA, and the North American Whippet Racing Association (NAWRA), while oval racing is sponsored by NOTRA. The standard track length of a straight race is 182.88 m, while the standard oval track is 350 m. A race meet is composed of four heats. Based on their placement in all four heats, dogs are given a total meet score. A dog's racing grade is a simplified assessment of its performance over the last three meets. As a result, a dog's racing grade will vary throughout its career as grade is reassessed following each meet. We used the WRA racing grades: Grade A is 15.0–29.0 points, grade B is 10.0–14.9 points, grade C is 4.0–9.9 points, and grade D is 0–3.9 points (http://www.whippetracing.org/Rules/2006/2006Chapter5.htm). We categorized dogs based on the highest grade ever achieved. Grades for 85 racing whippets were obtained from the WRA website (http://www.whippetracing.org). Regression analysis. We employed least-squares regression to estimate the allelic substitution (a) and dominance (d) effects of the mutation using a Falconer parameterization for genotypic means [24]. Briefly, we assumed the phenotypes within genotypic classes are normally distributed with mean for wild type (+/+), heterozygotes (mh/+), and homozygotes (mh/mh) of μ+/+ = μ − a, μ mh/ + = μ + d, and μ mh/mh = μ + a, and with common variance σ2 within classes. This amounts to using two “dummy” variables to encode the design matrix for the regression with values (−1, 0, and 1) and (0, 1, and 0) for the genotype classes (+/+, +/mh, and mh/mh). All measurements were normalized (i.e., mean subtracted and observations divided by the standard deviation) and Q-Q plots inspected visually to assess the appropriateness of normality assumption within genotypic classes. All statistical analyses were carried out using R 2.4.1 (www.r-project.org). Analysis of population structure. We genotyped 32 unlinked microsatellite markers [11] in 84 whippets with racing grades. All loci were found to be variable with a total of 135 alleles segregating across all markers. We used GDA [25] to calculate Wright's fixation index (FST) and estimated kinship coefficients using Ritland's method [26] and Rousset's genetic distance [27] using Spagedi 1.2f [28]. Population clustering was assayed using the Bayesian clustering algorithm Structure [12], which assumes Hardy-Weinberg equilibrium within clusters and InStruct [13], a Structure-like algorithm that estimates a generalized inbreeding coefficient for each cluster. A neighbor-joining tree was constructed by using Rousset's genetic distance [27] as input into Phylip 3.66 (http://evolution.genetics.washington.edu/phylip.html) and racing grade state was traced across the tree using MacClade 4.0 (http://macclade.org/) (Figure S1). We analyzed the control loci for association between genotype and racing grade using standard logistic regression analysis for differentiating A racers from B, C, or D racers. For each control locus, we fit a saturated model with nl parameters, where nl is the number of microsatellite alleles found at locus l (each analysis had (nl − 1) allele effects and one intercept parameter). Figure S2 shows the distribution of p-values for the 73 allele effects with p-values below 0.98. In total there were (135 − 32) = 103 independently estimated allele effects, but for 30 of these there was little power to detect an effect because so few dogs carried the allele. Sequencing of the MSTN gene and SNP genotyping. The entire canine MSTN gene was sequenced except for a 1,039-bp GC-rich region in intron one. Twelve pairs of overlapping primers covering the remaining regions of the gene and three primer pairs for SNP genotyping were designed using Primer 3 software [29] (http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi). Exon/intron boun-daries were based on the complete canine MSTN mRNA sequence. The resulting amplicons averaged 700 bp in length (653 to 799 bp). PCR was performed in a total volume of 10 μl containing 10 ng of dog DNA, 1× reaction buffer (Applied Biosystems, http://www.appliedbiosystems.com), 0.1 mM dNTP (Promega, http://www.promega.com), 1.5 mM MgCl2, 0.5 U of AmpliTaq Gold polymerase (Applied Biosystems) and 0.03 μM each specific primer. Touchdown PCR was carried out as follows: 7 min at 95 °C followed by 20 cycles of 30 s at 95 °C, 30 s at annealing temperature (beginning at 61 °C and decreasing 0.5 °C per cycle) and 30 s at 72 °C then 20 cycles of 30 s at 95 °C, 30 s at 51 °C and 30 s at 72 °C and a final extension phase for 3 min at 72 °C. The resulting PCR products were sequenced using Big Dye version 3.1 on an ABI 3730xl capillary sequencer (Applied Biosystems). Sequence reads were aligned and analyzed using Phred, Phrap, and Consed [30,31,32]. Polyphred [33] was used to assist in the identification of all SNPs and indel polymorphisms. Supporting Information Figure S1 Neighbor-Joining Tree for 84 Whippets with Racing Grade The tree was estimated using Rousset's genetic distance [27] from 32 unlinked microsatellite loci with racing grade traced using MacClade 4.0 (red = A, orange = B, aqua = C, and purple = D). Unique identifiers and racing grade are listed above each dog. Black boxes denote dogs that carry the 2-bp deletion and white boxes denote +/+ dogs. (32 KB PDF) Click here for additional data file. Figure S2 Logistic Regression of Racing Grade on Genotype The distribution of nominal p-values for logistic regression of racing grade (A versus B, C, or D) on genotype is shown for 73 alleles spanning 32 unlinked microsatellite loci. (A) Empirical cumulative distribution of p-values (open circles). The solid line represents the expected distribution under the null hypothesis of no association between genotype and racing grade. (B) Histogram of p-values on a log scale showing the location of the p-value for the 2-bp deletion. (132 KB PDF) Click here for additional data file. Accession Numbers The Genbank (http://www.ncbi.nlm.nih.gov/gquery/gquery.fcgi) accession number for the complete canine MSTN mRNA sequence is AY367768. The Genbank accession number for the MSTN protein is NP_01002959.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            The role of myostatin in muscle wasting: an overview

            Myostatin is an extracellular cytokine mostly expressed in skeletal muscles and known to play a crucial role in the negative regulation of muscle mass. Upon the binding to activin type IIB receptor, myostatin can initiate several different signalling cascades resulting in the upregulation of the atrogenes and downregulation of the important for myogenesis genes. Muscle size is regulated via a complex interplay of myostatin signalling with the insulin-like growth factor 1/phosphatidylinositol 3-kinase/Akt pathway responsible for increase in protein synthesis in muscle. Therefore, the regulation of muscle weight is a process in which myostatin plays a central role but the mechanism of its action and signalling cascades are not fully understood. Myostatin upregulation was observed in the pathogenesis of muscle wasting during cachexia associated with different diseases (i.e. cancer, heart failure, HIV). Characterisation of myostatin signalling is therefore a perspective direction in the treatment development for cachexia. The current review covers the present knowledge about myostatin signalling pathways leading to muscle wasting and the state of therapy approaches via the regulation of myostatin and/or its downstream targets in cachexia.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Myostatin propeptide-mediated amelioration of dystrophic pathophysiology.

              Mutations in myostatin (GDF8) cause marked increases in muscle mass, suggesting that this transforming growth factor-beta (TGF-beta) superfamily member negatively regulates muscle growth. Myostatin blockade therefore offers a strategy for reversing muscle wasting in Duchenne's muscular dystrophy (DMD) without resorting to genetic manipulation. Here, we demonstrate that pharmacological blockade using a myostatin propeptide stabilized by fusion to IgG-Fc improved pathophysiology of the mdx mouse model of DMD. Functional benefits evidenced by specific force improvement, exceeded those reported previously using myostatin antibody-mediated blockade. More importantly, use of a propeptide blockade strategy obviates possibilities of anti-idiotypic responses that could potentially limit the effectiveness of antibody-mediated myostatin blockade strategies over time. This study provides a novel pharmacological strategy for treatment of diseases associated with muscle wasting such as DMD and since it uses an endogenous inhibitor of myostatin should help circumvent technical hurdles and toxicity associated with conventional gene or cell based therapies.
                Bookmark

                Author and article information

                Contributors
                617-674-7119 , Michael.StAndre@pfizer.com
                Mark.Johnson1@pfizer.com
                Prashant.Bansal@parexel.com
                Jeremy.Wellen@pfizer.com
                Andrew.Robertson@pfizer.com
                Alan.C.Opsahl@pfizer.com
                Peter.Burch@summitplc.com
                Pbialek71@gmail.com
                carl@solidbio.com
                Jane.Owens@pfizer.com
                Journal
                Skelet Muscle
                Skelet Muscle
                Skeletal Muscle
                BioMed Central (London )
                2044-5040
                9 November 2017
                9 November 2017
                2017
                : 7
                : 25
                Affiliations
                [1 ]ISNI 0000 0000 8800 7493, GRID grid.410513.2, Rare Disease Research Unit, , Pfizer Inc., ; 610 Main Street, Cambridge, MA 02139 USA
                [2 ]ISNI 0000 0004 0367 5222, GRID grid.475010.7, NIGMS Training Program in Biomolecular Pharmacology, Department of Pharmacology & Experimental Therapeutics, , Boston University School of Medicine, ; Boston, MA USA
                [3 ]ISNI 0000 0000 8800 7493, GRID grid.410513.2, Early Clinical Development, , Pfizer Inc., ; Cambridge, MA USA
                [4 ]ISNI 0000 0000 8800 7493, GRID grid.410513.2, Investigative Pathology, , Pfizer Inc., ; Groton, CT USA
                [5 ]ISNI 0000 0000 8800 7493, GRID grid.410513.2, Research and Development Drug Safety, , Pfizer Inc., ; Groton, CT USA
                [6 ]Present Address: PAREXEL Informatics, Billerica, MA USA
                [7 ]Present Address: Summit Therapeutics, Cambridge, MA USA
                [8 ]Present Address: Solid Biosciences, Cambridge, MA USA
                [9 ]Present Address: Proteostasis Therapeutics, Cambridge, MA USA
                Article
                141
                10.1186/s13395-017-0141-y
                5679155
                29121992
                c5071b33-a062-4144-8ca3-7c91faa0de74
                © The Author(s). 2017

                Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

                History
                : 10 July 2017
                : 23 October 2017
                Funding
                Funded by: FundRef http://dx.doi.org/10.13039/100004319, Pfizer;
                Categories
                Research
                Custom metadata
                © The Author(s) 2017

                Rheumatology
                myostatin,hypertrophy,skeletal muscle,duchenne muscular dystrophy,monoclonal antibody,mdx
                Rheumatology
                myostatin, hypertrophy, skeletal muscle, duchenne muscular dystrophy, monoclonal antibody, mdx

                Comments

                Comment on this article